Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLS
Previous Symbol
CUSIPN/A
Phone502-241-4114
Debt
Debt-to-Equity Ratio0.12
Current Ratio26.02
Quick Ratio26.02
Price-To-Earnings
Trailing P/E Ratio-4.15
Forward P/E Ratio-6.93
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.96 per share
Price / Book5.15
Profitability
EPS (Most Recent Fiscal Year)($3.67)
Net Income$-51,000,000.00
Net MarginsN/A
Return on Equity-83.10%
Return on Assets-53.69%
Miscellaneous
Employees39
Outstanding Shares56,180,000
Market Cap$828.07 million
OptionableNot Optionable
Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions
What is Apellis Pharmaceuticals' stock symbol?
Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."
How were Apellis Pharmaceuticals' earnings last quarter?
Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.64) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.05. View Apellis Pharmaceuticals' Earnings History.
What price target have analysts set for APLS?
6 equities research analysts have issued 12-month price targets for Apellis Pharmaceuticals' shares. Their predictions range from $23.00 to $53.00. On average, they expect Apellis Pharmaceuticals' share price to reach $38.20 in the next year. This suggests a possible upside of 150.7% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.
What is the consensus analysts' recommendation for Apellis Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.
What are Wall Street analysts saying about Apellis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (10/8/2018)
- 2. Cantor Fitzgerald analysts commented, "Apellis is developing APL-2, an investigational C3 inhibitor for complement-mediated diseases. In our view, APLS shares offer a compelling risk-reward profile due to the large market potential and compelling efficacy profile in PNH and geographic atrophy (GA). Valuation Summary We arrive at our 12-month price target of $53/share by assessing the after-tax, risk- adjusted NPV of potential future cash flows from APL-2." (9/4/2018)
Has Apellis Pharmaceuticals been receiving favorable news coverage?
Media coverage about APLS stock has trended somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Apellis Pharmaceuticals' key competitors?
Some companies that are related to Apellis Pharmaceuticals include Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Mallinckrodt (MNK), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Allakos (ALLK), Supernus Pharmaceuticals (SUPN), Akcea Therapeutics (AKCA) and Myokardia (MYOK).
Who are Apellis Pharmaceuticals' key executives?
Apellis Pharmaceuticals' management team includes the folowing people:
- Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Pascal Deschatelets, Co-Founder & COO (Age 48)
- Mr. Timothy E. Sullivan, CFO & Treasurer (Age 47)
- Dr. Federico Grossi M.D., Ph.D., Co-Founder & Sr. VP of Clinical Devel. (Age 44)
- Mr. David O. Watson, Gen. Counsel & VP of Corp. Devel. (Age 45)
When did Apellis Pharmaceuticals IPO?
(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.
Who are Apellis Pharmaceuticals' major shareholders?
Apellis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.08%), Vivo Capital LLC (2.41%), Victory Capital Management Inc. (2.40%), Jennison Associates LLC (1.02%), FMR LLC (1.01%) and Candriam Luxembourg S.C.A. (0.92%). Company insiders that own Apellis Pharmaceuticals stock include David O Watson, Global Strategic Fund I Venbio, Lukas Scheibler and Morningside Venture Investment. View Institutional Ownership Trends for Apellis Pharmaceuticals.
Which major investors are selling Apellis Pharmaceuticals stock?
Which major investors are buying Apellis Pharmaceuticals stock?
APLS stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Candriam Luxembourg S.C.A., BlackRock Inc., Citadel Advisors LLC, VHCP Management III LLC, Prudential Financial Inc., Swiss National Bank and Dynamic Technology Lab Private Ltd. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Global Strategic Fund I Venbio, Lukas Scheibler and Morningside Venture Investment. View Insider Buying and Selling for Apellis Pharmaceuticals.
How do I buy shares of Apellis Pharmaceuticals?
Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apellis Pharmaceuticals' stock price today?
One share of APLS stock can currently be purchased for approximately $15.24.
How big of a company is Apellis Pharmaceuticals?
Apellis Pharmaceuticals has a market capitalization of $828.07 million. The company earns $-51,000,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Apellis Pharmaceuticals employs 39 workers across the globe.
What is Apellis Pharmaceuticals' official website?
How can I contact Apellis Pharmaceuticals?
Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]
MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
